EVIDENCE LOCKER

Your body got stapled to someone else's spreadsheet in 1942.

Employer-sponsored health insurance originated during WWII wage controls. The 1942 Stabilization Act froze wages; employers offered health benefits as compensation instead. IRS later codified the tax exclusion via Revenue Ruling 54-264.

An accident that's been running for about eighty-four years.

Math check: 2026 - 1942 = 84 years. Accurate as of recording date.

Christopher McNaughton was a college student with ulcerative colitis. His account was flagged "HIGH DOLLAR."

ProPublica investigation (Feb 2023) based on internal UnitedHealthcare documents obtained through litigation. McNaughton v. UnitedHealthcare (lawsuit, settled Feb 2023). Internal documents revealed the "HIGH DOLLAR" patient classification used to flag costly accounts.

"Why not just deny them all and see which ones come back? From a cost perspective, it makes perfect sense."

Quote attributed to a former insurance executive. Referenced in investigative reporting on industry denial practices. Exact original source document pending verification.

Humira. Seventy-two thousand dollar a year drug.

Humira (adalimumab) list price widely reported at approximately $72,000-$80,000/year before biosimilar competition. At the time of Joey's case, $72,000/year was the standard list price for the brand-name product. Manufacturer pricing data.

Every prescription runs through a pharmacy benefit manager. A PBM. Every prescription generates a rebate. The test? Zero kickback.

PBM rebate structures are well-documented. Prescription drugs generate manufacturer rebates paid to PBMs and plan sponsors. Diagnostic tests and lab work do not generate comparable rebates.
FTC Interim Report on PBMs (2024): <a href="https://www.ftc.gov/reports/pharmacy-benefit-managers-report">https://www.ftc.gov/reports/pharmacy-benefit-managers-report</a>

Blue Cross has no legal obligation to act in Joey's or his company's best interest.

Under ERISA, third-party administrators of self-insured plans have limited fiduciary obligations compared to fully insured plans. The TPA's contractual duty is to the plan document, not to individual members. This structural gap is widely documented in benefits law.

Primary source: Joey. $75/week x 52 = $3,900/year. National context from KFF 2025 Employer Health Benefits Survey: Average worker contribution is $1,440/year for single coverage and $6,850/year for family coverage.

Primary source: Joey. $75/week x 52 = $3,900/year. National context from KFF 2025 Employer Health Benefits Survey: Average worker contribution is $1,440/year for single coverage and $6,850/year for family coverage.

His employer pays Blue Cross another $27,000 a year to manage the plan.

Primary source: Joey's W-2 and employer benefits documentation. As spoken in the episode: $27,000/year. 2025 update: Joey's W-2 shows employer contribution of $34,069.35, a 26% increase. National context from KFF 2025: Average total premium for family coverage is $26,993. Employers pay an average of $20,143.

The company that makes Humira pays Blue Cross thirty to forty percent of that $72,000 list price back as a kickback. Call it $25,000.

PBM rebate ranges on brand-name biologics widely reported at 30-40% of list price per FTC findings and congressional testimony. $72,000 x 30-40% = $21,600-$28,800. "$25,000" is a reasonable midpoint estimate. Specific rebate percentages vary by plan and PBM contract.

Nobody can see the rebate. Not Joey. Not his employer. Not the pharmacist.

PBM rebate opacity documented by FTC and congressional investigations. Rebate agreements between manufacturers and PBMs are typically confidential. Employers in self-insured plans often do not see exact rebate amounts. Patients and pharmacists have no visibility into rebate flows.

Cigna doctors denied 300,000 claims over two months. The average review time per claim was 1.2 seconds.

ProPublica investigation (March 2023) based on internal Cigna data and audit logs. Cigna's PxDx system was used to deny approximately 300,000 claims over two months. Audit logs showed average review time of 1.2 seconds per claim. Doctors approved flagged denials in bulk without reading patient files.

One doctor denied 121,000 claims in sixty days.

ProPublica (March 2023). Internal audit logs showed one medical director processing approximately 121,000 claim denials in a two-month period through the PxDx system.

The internal system is called PXDX. Procedure by diagnosis. Page 47 of their internal documents.

ProPublica (March 2023). PxDx (Procedure-to-Diagnosis) is Cigna's internal rules engine that cross-references procedure codes against diagnosis codes. If the combination is not in the approved pairs, the claim is flagged for denial. Referenced in Kisting-Leung v. Cigna class action court filings. Page 47 reference from internal documents cited in litigation.

UnitedHealth built a tool called nH Predict. The algorithm looked at six million patient records and decided your recovery should average out to fourteen days.

STAT News "Denied by AI" investigative series (2023-2024). nH Predict developed by NaviHealth, a UnitedHealth subsidiary (now Home & Community Care under Optum). Tool uses six million historical patient records to generate expected length-of-stay predictions for post-acute care. Senate Permanent Subcommittee on Investigations "Refusal of Recovery" report (2024) documented cases where nH Predict cutoffs overrode treating physician recommendations. UnitedHealth's post-acute care denial rate more than doubled after deploying NaviHealth, climbing from 8.7% to 22.7% between 2019 and 2022.

A federal lawsuit alleges UnitedHealth knew the algorithm was wrong ninety percent of the time when families actually fought back.

Estate of Lokken v. UnitedHealth Group -- Class Action Complaint (D. Minn. Nov 2023). Plaintiff allegation based on internal data showing approximately 90% overturn rate when families appealed nH Predict-based coverage terminations. Case still actively advancing through federal court as of March 2026 after judge ordered broad document discovery in March 2025.

When people do appeal, ninety percent win.

The episode rounds to "ninety percent." Three underlying data points support the 80-90% range: (1) KFF January 2026 analysis of CMS data shows 80.7% of appealed Medicare Advantage prior authorization denials were partially or fully overturned in 2024. (2) The Lokken lawsuit alleges approximately 90% overturn rate for nH Predict appeals specifically. (3) A January 2026 Health Affairs study from Stanford found an 82% overturn rate across MA appeals.

0.2% appeal.

KFF analysis of ACA marketplace data. In 2024, consumers appealed fewer than 1% of approximately 85 million in-network denied claims (262,982 appeals filed = approximately 0.3%). The 0.2% figure cited in the episode comes from earlier KFF ACA marketplace analyses. Both figures support the thesis. Scope: ACA marketplace plans on HealthCare.gov only, not all insured populations. Medicare Advantage appeal rates are higher (11.5% in 2024) but still low relative to the overturn rate.

I buy $47 of UNH stock. That's about one-sixth of a share. Fractional shareholders still get to attend the annual meeting.
Line was flubbed in recording. Said 47 Shares

UNH share price at time of recording: approximately $280-300. $47 / ~$282 = roughly 1/6 of a share. Fractional share ownership through most brokerages does technically entitle holders to shareholder meeting attendance, though policies vary by broker and company.